Dexamethasone implant for the treatment of persistent diabetic macular oedema despite long-term treatment with bevacizumab

Clinical and Experimental Ophthalmology

Volumn 47, Issue 2, 2019, Pages 287-289

  Joe, Aaron W ^a   Wickremasinghe, Sanjeewa S ^b   Gillies, Mark C ^b   Nguyen, Vuong ^a   Lim, Lyndell L ^b   Mehta, Hemal ^a,c   Fraser Bell, Samantha ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE; ANGIOGENESIS INHIBITOR; GLUCOCORTICOID; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGED; BEST CORRECTED VISUAL ACUITY; CENTRAL MACULAR THICKNESS; CLINICAL ARTICLE; DIABETIC MACULAR EDEMA; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; INTRAOCULAR PRESSURE; LETTER; LONG TERM CARE; MALE; MONOTHERAPY; PROSPECTIVE STUDY; TREATMENT OUTCOME; TREND STUDY; DIABETIC RETINOPATHY; DRUG IMPLANT; DRUG SUBSTITUTION; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MIDDLE AGED; PATHOPHYSIOLOGY; VISUAL ACUITY;

AGED; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; DEXAMETHASONE; DIABETIC RETINOPATHY; DRUG IMPLANTS; DRUG SUBSTITUTION; FEMALE; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 85056258931     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/ceo.13371     Document Type: Letter

References (5)

1. Bressler NM, Beaulieu WT, Glassman AR, et al., for the Diabetic Retinopathy Clinical Research Network; Persistent macular thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for central-involved diabetic macular edema with vision impairment: a secondary analysis of a randomized clinical trial. JAMA Ophthalmol. 2018;136(3):257-269.
2. Brown DM, Nguyen QD, Marcus DM, et al., RIDE and RISE Research Group; Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120(10):2013-2022.
3. Mehta H, Hennings C, Gillies MC, Nguyen V, Campain A, Fraser-Bell S. Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. Cochrane Database Syst Rev. 2018;4:Cd011599.
4. Gillies MC, Lim LL, Campain A, et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology. 2014;121(12):2473-2481.
5. Maturi RK, Glassman AR, Liu D, et al., for the Diabetic Retinopathy Clinical Research Network; Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: a DRCR network phase 2 randomized clinical trial. JAMA Ophthalmol. 2018;136(1):29-38.